The positive implication of this particular mechanism relies on the ability of mAb to leave intact the antiangiogenic activity of the VEGFR-1 soluble form (sVEGFR-1), which is released by endothelial and tumor cells in the ECM, where it sequesters receptor ligands (decoy receptor function) [6]. This evidence concerns the gene FLT1 and neoplasm.